慢性阻塞性肺疾病患者接种季节性流感疫苗和23价肺炎球菌多糖疫苗的安全性观察

Safety of seasonal influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in patients with chronic obstructive pulmonary disease

目的评价慢性阻塞性肺疾病(COPD)患者接种三价季节性流感疫苗(TIV)和23价肺炎球菌多糖疫苗(PPV23)的安全性。方法在河北省唐山市10家医院招募COPD患者,接种1剂次TIV和/或1剂次PPV23,主动观察接种后28d不良事件,分析不良事件发生率。结果COPD患者接种TIV、PPV23后不良事件总发生率分别为5.13%(22/429)、6.44%(25/388),其中局部不良事件发生率分别为2.80%(12例)、6.19%(24例),全身不良事件发生率分别为2.33%(10例)、0.26%(1例)。两种疫苗最常见的局部不良事件均为接种部位疼痛,发生率分别为2.80%(12例)、6.19%(24例),最常见的全身不良事件为发热,发生率分别为1.63%(7例)、0.26%(1例)。所有不良事件的严重程度均为1级或2级。结论本研究COPD患者接种1剂次TIV和PPV23的安全性良好。

Objective To evaluate the safety of trivalent influenza vaccine(TIV)and 23-valent pneumococcal polysaccharide vaccine(PPV23)in patients with chronic obstructive pulmonary disease(COPD).Methods We recruited COPD patients from 10 hospitals of Tangshan city in Hebei province.Patients received one dose of TIV and/or PPV23.We actively observed for adverse events within 28 days after vaccination and determined incidences of adverse events.Results Overall incidences of adverse events were 5.13%(22/249)and 6.44%(25/388)among COPD patients after TIV and PPV23 vaccination,respectively,with local adverse event rates of 2.80%(12 cases)and 6.19%(24 cases)and systemic adverse event rates of 2.33%(10 cases)and 0.26%(1 case).The most common local adverse event for the two vaccines was injection-site pain,with incidences of 2.80%(12 cases)and 6.19%(24 cases),respectively.The most common systemic adverse event for the two vaccines was fever,with incidences of 1.63%(7 cases)and 0.26%(1 case),respectively.The severity levels of all adverse events were grades 1 or 2.Conclusions Vaccination of COPD patients with one dose of TIV or PPV23 was safe.